Korsana Biosciences (KRSA) Stock
What Korsana Biosciences's price implies, from its SEC filings.
Key numbers
- P/E (trailing)
- 0.90x
- P/E (forward)
- -8.76x
- Revenue growth
- +3.7%
- Debt / equity
- 0.00x
What Korsana Biosciences's price implies
Korsana Biosciences's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from Korsana Biosciences's 10-K filings.
Korsana Biosciences revenue and free cash flow
FY2018–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4M | $297,000 | $0 | $2M | $2M |
| Net income | -$52M | -$44M | -$5M | -$3M | -$4M |
| Free cash flow | -$37M | -$41M | — | — | — |
| EPS (diluted) | -$0.53 | -$20.28 | -$2.25 | -$1.21 | -$1.11 |
| Operating margin | -1,400.2% | -6,242.4% | — | -181.4% | -239.8% |
Where the revenue comes from
By products, fiscal 2025. By year
Superinvestors who own KRSA
From each investor's latest 13F filing (what a 13F shows).
None of the superinvestors we track held KRSA in their latest 13F.
Korsana Biosciences insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of KRSA in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from KRSA's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Korsana Biosciences compares
Korsana Biosciences's P/E is higher than 2% of Healthcare companies and 1% of the 2,508 companies with a P/E figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| P/E | 2% | 1% |
| Revenue growth | 33% | 32% |
| ROE | 50% | 18% |
Questions about Korsana Biosciences
Are Korsana Biosciences insiders buying the stock?
No open-market insider purchases of KRSA in the last 12 months, according to SEC Form 4 filings.
Companies like Korsana Biosciences
Armata Pharmaceuticals Inc (ARMP)$130MInnate Pharma (IPHA)$135MSpruce Biosciences, Inc. (SPRB)$128MCompass Therapeutics Inc. (CMPX)$137MJyong Biotech Ltd. (MENS)$137MProtara Therapeutics, Inc. (TARA)$138MPyxis Oncology, Inc. (PYXS)$139MHumacyte Inc (HUMA)$124MProQR Therapeutics N.V. (PRQR)$141M All Healthcare stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.